Tango Therapeutics Inc
NASDAQ:TNGX

Watchlist Manager
Tango Therapeutics Inc Logo
Tango Therapeutics Inc
NASDAQ:TNGX
Watchlist
Price: 3.19 USD 2.9% Market Closed
Market Cap: 342.7m USD
Have any thoughts about
Tango Therapeutics Inc?
Write Note

Tango Therapeutics Inc
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Tango Therapeutics Inc
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Tango Therapeutics Inc
NASDAQ:TNGX
Additional Paid In Capital
$624.1m
CAGR 3-Years
396%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Additional Paid In Capital
$21.2B
CAGR 3-Years
5%
CAGR 5-Years
7%
CAGR 10-Years
18%
Gilead Sciences Inc
NASDAQ:GILD
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Additional Paid In Capital
$6.9B
CAGR 3-Years
-1%
CAGR 5-Years
-2%
CAGR 10-Years
2%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Additional Paid In Capital
$12.7B
CAGR 3-Years
17%
CAGR 5-Years
24%
CAGR 10-Years
18%
No Stocks Found

Tango Therapeutics Inc
Glance View

Market Cap
342.7m USD
Industry
Biotechnology

Tango Therapeutics, Inc. operates as a biotechnology company that engages in discovering and delivering precision cancer medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 91 full-time employees. The company went IPO on 2020-09-03. The firm is engaged in the discovery and development of drugs at tumor suppressor gene loss in patients with unmet medical need. The Company’s product candidates include TNG908 and ubiquitin-specific protease 1 (USP1). Its TNG908, is a potent, selective, synthetic lethal, small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), which is designed to work selectively in cancer cells with an methylthioadenosine phosphorylase (MTAP) deletion. The MTAP-deletion occurs in all human tumors, including cancers with unmet need, such as squamous cell lung, esophageal and bladder cancer. The Company’s USP1, is a synthetic lethal that target for BRCA1-mutant breast, ovarian and prostate cancer. The USP1 treats a patient population for poly (ADP-ribose) polymerase (PARP) inhibitors that are operative against cancers with BRCA1 and BRCA2 mutations.

TNGX Intrinsic Value
2.78 USD
Overvaluation 13%
Intrinsic Value
Price

See Also

What is Tango Therapeutics Inc's Additional Paid In Capital?
Additional Paid In Capital
624.1m USD

Based on the financial report for Dec 31, 2023, Tango Therapeutics Inc's Additional Paid In Capital amounts to 624.1m USD.

What is Tango Therapeutics Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 3Y
396%

Over the last year, the Additional Paid In Capital growth was 19%. The average annual Additional Paid In Capital growth rates for Tango Therapeutics Inc have been 396% over the past three years .

Back to Top